Abstract
Significant improvement in survival outcome with the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors has been shown in advanced non-small cell lung cancer (NSCLC) patients compared with chemotherapy. However, the full spectrum of toxic events of PD-1/PD-L1 inhibitors was not well characterized. We conducted a comprehensive meta-analysis to state the safety profile of PD-1/PD-L1 inhibitors in NSCLC, and identify the exact incidence and relative risk (RR) of both summary and detailed AEs. Electronic databases (PubMed, EMBASE and the Cochrane library databases) and major conference proceedings were systematically searched for all clinical trials in lung cancer using PD-1/PD-L1 inhibitors. Eligible studies included randomized controlled trials (RCTs) comparing PD-1/PD-L1 inhibitors with chemotherapy in NSCLC patients reporting all-grade (1-4) or high-grade (3-4) AEs [toxic symptoms, hematologic toxicities, and immune-related AEs (irAEs)], treatment discontinuation due to toxicities, or toxic deaths. The pooled incidence, RR, and corresponding 95% confidence interval (CI) of toxicity outcomes were calculated. A total of 4413 patients from 8 RCTs (3 with nivolumab; 2 with atezolizumab, and 3 with pembrolizuma) ...Continue Reading
References
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Oct 6, 1997·BMJ : British Medical Journal·M EggerC Minder
Jan 5, 2014·PloS One·Nikola PanicStefania Boccia
Jul 10, 2014·Journal of the National Cancer Institute·Bryce B ReeveDeborah Watkins Bruner
Sep 16, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J NaidooJ D Wolchok
Nov 13, 2015·American Journal of Clinical Oncology·Elizabeth I Buchbinder, Anupam Desai
Dec 30, 2015·Lancet·Roy S HerbstEdward B Garon
Jan 15, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M MichotO Lambotte
Mar 14, 2016·Lancet·Louis FehrenbacherUNKNOWN POPLAR Study Group
Jul 21, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sophie Cousin, Antoine Italiano
Aug 19, 2016·The Oncologist·Grainne M O'KaneNatasha B Leighl
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Dec 17, 2016·Lancet·Achim RittmeyerUNKNOWN OAK Study Group
Mar 2, 2017·Cancer Immunology Research·Guillermo De VelascoToni K Choueiri
Apr 6, 2017·Journal of Biomedical Science·Yoshiko IwaiTasuku Honjo
Aug 25, 2017·The Oncologist·Lee Pai-ScherfRichard Pazdur
Sep 17, 2017·Oncotarget·Ang LiShi-Qing Feng
Apr 19, 2018·Annals of Translational Medicine·Young Kwang ChaeFrancis J Giles
May 23, 2018·Journal of the National Comprehensive Cancer Network : JNCCN·John A Thompson
Citations
Jul 26, 2019·JAMA Oncology·Suzanne L TopalianMario Sznol
Oct 5, 2019·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Laura Lorenzo-Sanz, Purificación Muñoz
Mar 4, 2020·Expert Opinion on Drug Safety·Alexandra M HaughDouglas B Johnson
Mar 5, 2020·Expert Opinion on Drug Safety·José Mª Mazarico GallegoLuis Paz-Ares
Mar 14, 2020·Journal of the Peripheral Nervous System : JPNS·Jordi BrunaHaralabos P Kalofonos
Aug 20, 2019·Journal of the National Cancer Institute. Monographs·Dorothy M K Keefe, Emma H Bateman
Jun 14, 2020·PharmacoEconomics Open·Christine M Cramer-van der WelleEwoudt M W van de Garde
Oct 15, 2019·Frontiers in Pharmacology·Siyao DengShun Lu
Jan 9, 2019·Frontiers in Pharmacology·Ke MaYuyang Zhang
Jun 27, 2020·Journal of Biochemical and Molecular Toxicology·Nilufer Ozdemir KutbayMehmet Erdogan
May 21, 2020·Wiener klinische Wochenschrift·Lucian BeerHelmut Prosch
Aug 9, 2019·Journal of the Peripheral Nervous System : JPNS·Dimitri PsimarasAndreas A Argyriou
Sep 11, 2020·Case Reports in Oncological Medicine·M L VickersR Chew
Nov 20, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Y YangH Ge
Mar 4, 2021·International Journal of Clinical Oncology·Shoko KawaiYukio Hosomi
Mar 3, 2021·Revue neurologique·R Bonomo, G Cavaletti
Mar 18, 2021·Medicine·Rui ZhangHuafang Wei
Jul 28, 2021·MAbs·Sujatha KumarDavid Jenkins
Dec 11, 2021·Frontiers in Immunology·Na LiXianquan Zhan